Recruiting PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT05404906

AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

Randomized, Multicenter, Phase 3 Study of Azacytidine (AZA) + Venetoclax as Maintenance Therapy in Patients With AML in Remissionin Younger Adults With Favorable-risk AML in First Remission After Conventional Chemotherapy

Sponsor: The First Affiliated Hospital of Soochow University

Conditions Acute Myeloid Leukemia (AML) in Remission

Interventions Azacitidine Supportive care Venetoclax

Updated 4 times since 2022 Last updated: Aug 18, 2022 Started: Jun 25, 2022 Primary completion: Jun 30, 2028 Completion: Jun 30, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Acute Myeloid Leukemia (AML) in Remission, this trial is actively recruiting participants. The trial is conducted by The First Affiliated Hospital of Soochow University and has accumulated 4 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Sep 2022 — Jul 2024 [monthly]

Recruiting PHASE2_PHASE3

Status: Not Yet Recruiting → Recruiting
Jul 2022 — Sep 2022 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Jun 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The First Affiliated Hospital of Soochow University

Data source: The First Affiliated Hospital of Soochow University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Suzhou, China